Aurinia Pharmaceuticals Inc AUPH
$15.47
+1.91%
at last close
Market Cap$2.06 billion
P/E Ratio6.76
Div Yield—
Volume826.3K
52-Week Range
$8.28$19.25
Analyst Ratings
- Consensus
- Hold — 1 Buy · 2 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $17.67 (+14.2% upside)
Key Stats
- Today's Range
- $14.90 – $15.49
- 50-Day Range
- $14.36 – $19.25
- 52-Week Range
- $8.28 – $19.25
- Volume
- 826K shs
- Average Volume
- 1.23 million shs
- Market Cap
- $2.06 billion
- P/E Ratio
- 6.76
- Dividend Yield
- —
Valuation
- P/E Ratio
- 6.76
- Price / Book
- 3.34
- Price / Sales
- 6.60
Short Interest
- Short Interest
- 7.43%
- Days to Cover
- 8.65
Financials (TTM)
- Revenue
- $311.51 million
- Net Income
- $314.11 million
- Net Margin
- 100.84%
- Return on Equity
- 51.09%
- Debt-to-Equity
- —
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Related Stocks
Compare head-to-head: AUPH vs LLY·AUPH vs JNJ·AUPH vs ABBV·AUPH vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.